{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:55:51Z","timestamp":1790214951548,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.vaccine.2021.02.052","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T16:56:37Z","timestamp":1614963397000},"page":"1812-1817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the vaccine adverse event reporting system"],"prefix":"10.1016","volume":"39","author":[{"given":"Emily Jane","family":"Woo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro L.","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.02.052_b0005","unstructured":"Flublok approval letter. http:\/\/wayback.archive-it.org\/7993\/20170723030119\/https:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm410628.htm; accessed 2\/22\/21."},{"key":"10.1016\/j.vaccine.2021.02.052_b0010","unstructured":"Flublok Quadrivalent approval letter. https:\/\/wayback.archive-it.org\/7993\/20190425010438\/https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM524738.pdf; accessed 10\/16\/20."},{"key":"10.1016\/j.vaccine.2021.02.052_b0015","unstructured":"Flublok Quadrivalent package insert. https:\/\/www.fda.gov\/media\/123144\/download; accessed 10\/16\/20."},{"issue":"5","key":"10.1016\/j.vaccine.2021.02.052_b0020","first-page":"777","article-title":"Clin Infect Dis","volume":"60","author":"Woo","year":"2015","journal-title":"Allergic reactions after egg-free recombinant influenza vaccine: reports to the US Vaccine Adverse Event Reporting System."},{"issue":"42","key":"10.1016\/j.vaccine.2021.02.052_b0025","doi-asserted-by":"crossref","first-page":"5618","DOI":"10.1016\/j.vaccine.2017.08.047","article-title":"Postmarketing safety surveillance of trivalent recombinant influenza vaccine: reports to the Vaccine Adverse Event Reporting System","volume":"35","author":"Woo","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.052_b0030","doi-asserted-by":"crossref","unstructured":"ACIP Grohskopf LA, Alyanak E, Broder KR, Blanton LH, Fry AM, Jernigan DB, Atmar RL. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 Influenza Season. MMWR Recomm Rep. 2020 Aug 21;69(8):1-24.","DOI":"10.15585\/mmwr.rr6908a1"},{"issue":"36","key":"10.1016\/j.vaccine.2021.02.052_b0035","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine."},{"issue":"1","key":"10.1016\/j.vaccine.2021.02.052_b0040","first-page":"1","article-title":"Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) United States, 1991\u20132001","volume":"52","author":"Zhou","year":"2003","journal-title":"MMWR Surveill Summ."},{"key":"10.1016\/j.vaccine.2021.02.052_b0045","unstructured":"Code of Federal Regulations. 21 600.80."},{"issue":"31","key":"10.1016\/j.vaccine.2021.02.052_b0050","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Brighton Collaboration Anaphylaxis Working Group. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.052_b0055","doi-asserted-by":"crossref","unstructured":"DuMouchel W, Pregibon D. Empirical Bayes screening for multi-item associations. Proceeding of the conference on knowledge discovery and data; 2001 Aug 26-29; San Diego (CA): ACM Press 67-76.","DOI":"10.1145\/502512.502526"},{"key":"10.1016\/j.vaccine.2021.02.052_b0060","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s Spontaneous Reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"issue":"43","key":"10.1016\/j.vaccine.2021.02.052_b0065","doi-asserted-by":"crossref","first-page":"6543","DOI":"10.1016\/j.vaccine.2019.08.045","article-title":"Surveillance for Guillain-Barr\u00e9 syndrome after 2015\u20132016 and 2016\u20132017 influenza vaccination of Medicare beneficiaries","volume":"37","author":"Arya","year":"2019","journal-title":"Vaccine."},{"issue":"24","key":"10.1016\/j.vaccine.2021.02.052_b0070","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Yuki","year":"2012","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.vaccine.2021.02.052_b0075","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1212\/WNL.0b013e3182904fcc","article-title":"Mortality in Guillain-Barr\u00e9 syndrome","volume":"80","author":"van den Berg","year":"2013","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.vaccine.2021.02.052_b0080","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1212\/WNL.52.3.635","article-title":"Fatal Guillain-Barr\u00e9 syndrome","volume":"52","author":"Lawn","year":"1999","journal-title":"Neurology."},{"issue":"2","key":"10.1016\/j.vaccine.2021.02.052_b0085","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barr\u00e9 syndrome following vaccination in the National Influenza Immunization Program, United States, 1976\u20131977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.02.052_b0090","unstructured":"IOM (Institute of Medicine). 2011. Adverse Effects of Vaccines: Evidence and Causality. Washington, DC: The National Academies Press."},{"issue":"3","key":"10.1016\/j.vaccine.2021.02.052_b0095","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/infdis\/jiaa543","article-title":"Guillain-Barr\u00e9 Syndrome After High-Dose Influenza Vaccine Administration in the United States, 2018\u20132019 Season","volume":"223","author":"Perez-Vilar","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.02.052_b0100","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1016\/j.vaccine.2019.05.041","article-title":"Surveillance for Guillain-Barr\u00e9 syndrome after influenza vaccination among U.S. Medicare beneficiaries during the 2017\u20132018 season","volume":"37","author":"Perez-Vilar","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.052_b0105","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1016\/j.vaccine.2017.03.087","article-title":"Near real-time surveillance for Guillain-Barr\u00e9 syndrome after influenza vaccination among the Medicare population, 2010\/11 to 2013\/14","volume":"35","author":"Sandhu","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.052_b0110","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2105\/AJPH.2011.300510","article-title":"Surveillance for Guillain-Barr\u00e9 syndrome after influenza vaccination among the Medicare population, 2009\u20132010","volume":"102","author":"Burwen","year":"2012","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2021.02.052_b0115","doi-asserted-by":"crossref","unstructured":"American College of Obstetricians and Gynecologists Committee on Obstetric Practice. ACOG Committee opinion no. 732: influenza vaccination during pregnancy. Obstet Gynecol 2018 Apr;131(4):e109\u2013e114.","DOI":"10.1097\/AOG.0000000000002588"},{"issue":"6","key":"10.1016\/j.vaccine.2021.02.052_b0120","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1303164","article-title":"Intussusception risk after rotavirus vaccination in US infants","volume":"370","author":"Yih","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21002322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21002322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:54:22Z","timestamp":1759402462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21002322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":24,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0264410X21002322"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.052","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the vaccine adverse event reporting system","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}